[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100563502":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":11,"centralContacts":19,"locations":25,"responsibleParty":87,"collaborators":11,"id":89,"slug":11,"hasResults":90,"nctId":91,"briefTitle":92,"officialTitle":93,"acronym":11,"eligibilityCriteria":94,"healthyVolunteers":90,"sex":95,"minAge":96,"maxAge":97,"enrollmentInfo":98,"targetDuration":11,"studyType":101,"phases":102,"briefSummary":104,"conditions":105,"keywords":11,"overallStatus":28,"whyStopped":11,"lastUpdateSubmitDate":109,"lastUpdatePostDateStruct":110,"startDateStruct":113,"completionDateStruct":115,"leadSponsor":117,"locationsCount":118},{"fullName":5,"class":6},"SCG Cell Therapy Pte. Ltd.","INDUSTRY",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"SCG101","EXPERIMENTAL",null,[13],"Biological: SCG101",[15],{"type":16,"name":9,"description":17,"armGroupLabels":18,"otherNames":11},"BIOLOGICAL","Infusion of HBsAg-specific TCR autologous T cells at assigned dose levels.",[9],[20],{"name":21,"role":22,"phone":23,"phoneExt":11,"email":24},"SCG Cell Therapy","CONTACT","021-50339500","clinicaltrials@scgcell.com",[26,38,47,56,65,74,78],{"facility":27,"status":28,"city":27,"state":29,"zip":30,"country":31,"cosmosGeoPoint":32,"geoPoint":37,"contacts":11},"Beijing","RECRUITING","Beijing Municipality","100020","China",{"type":33,"coordinates":34},"Point",[35,36],116.39723,39.9075,{"lat":36,"lon":35},{"facility":39,"status":28,"city":39,"state":40,"zip":41,"country":31,"cosmosGeoPoint":42,"geoPoint":46,"contacts":11},"Guangzhou","Guangdong","510000",{"type":33,"coordinates":43},[44,45],113.25,23.11667,{"lat":45,"lon":44},{"facility":48,"status":28,"city":48,"state":49,"zip":50,"country":31,"cosmosGeoPoint":51,"geoPoint":55,"contacts":11},"Zhengzhou","Henan","450003",{"type":33,"coordinates":52},[53,54],113.64861,34.75778,{"lat":54,"lon":53},{"facility":57,"status":28,"city":57,"state":58,"zip":59,"country":31,"cosmosGeoPoint":60,"geoPoint":64,"contacts":11},"Changchun","Jilin","130000",{"type":33,"coordinates":61},[62,63],125.32278,43.88,{"lat":63,"lon":62},{"facility":66,"status":28,"city":66,"state":67,"zip":68,"country":31,"cosmosGeoPoint":69,"geoPoint":73,"contacts":11},"Shenyang","Liaoning","110000",{"type":33,"coordinates":70},[71,72],123.43278,41.79222,{"lat":72,"lon":71},{"facility":75,"status":28,"city":75,"state":76,"zip":77,"country":31,"cosmosGeoPoint":11,"geoPoint":11,"contacts":11},"Ji'nan","Shandong","250000",{"facility":79,"status":28,"city":79,"state":80,"zip":81,"country":31,"cosmosGeoPoint":82,"geoPoint":86,"contacts":11},"Shanghai","Shanghai Municipality","200000",{"type":33,"coordinates":83},[84,85],121.45806,31.22222,{"lat":85,"lon":84},{"type":88,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100563502",false,"NCT06617000","A Study of SCG101 TCR-T Cell Therpay in the Treatment of Subjects With Hepatitis B Virus-Related","A Phase 1, Multicenter Study of SCG101 in the Treatment of Subjects With Hepatitis B Virus-Related Hepatocellular Carcinoma","Inclusion Criteria:\n\n* Histologically or cytologically confirmed Hepatocellular carcinoma (HCC)\n* Subjects with HCC who have received standard systemic therapies\n* HLA-A \\*02\n* BCLC stage B or C\n* Child-pugh score ≤ 7 ol\n* Serum HBeAg negative, serum (or tumor tissue) HBsAg positive, and serum HBV-DNA must be ≤ 1 × 1000 IU\u002Fml\n* Have at least one measurable leasion at baseline as per mRECIST and iRECIST\n* Life expectancy of 3 months or greater\n* The organ function is in good condition.\n\nExclusion Criteria:\n\n* Subjects with history of another primary cancer within 5 years\n* Central nervous system metastasis and clinically significant central nervous system disease\n* Previous or current coexistence of hepatic encephalopathy\n* Currently present with symptomatic third space fluid accumulation\n* Hypertension that is poorly controlled, as determined by researchers (i.e., arterial hypertension that remains uncontrolled despite standard treatment)\n* Known history of neurological or mental disorder, including epilepsy or dementia\n* Suffering from active autoimmune diseases, or other significant ongoing immune rejection based on pathology and clinical diagnosis\n* Prior exposure to any cell therapy such as, but not limited to killer (NK) cells, cytokine-induced killer (CIK) cells, dendritic cells (DC), cytotoxic T lymphocytes (CTL), stem cell therapy\n* Positive for HCV - RNA test or positive for HAV IgM antibody or positive for HDV IgM antibody; or there is current evidence indicating the presence of HEV infection\n* Allergy to immunotherapy drugs and lymphodepleting chemotherapy (cyclophosphamide and fludarabine)\n* Any condition which, in the investigator's opinion, makes the subject unsuitable for trial participation","ALL","18 Years","70 Years",{"count":99,"type":100},38,"ESTIMATED","INTERVENTIONAL",[103],"PHASE1","This is a Phase I clinical study aimed to assess the safety, tolerability, and efficacy of SCG101 monotherapy for patients with HBV-HCC.",[106,107,108],"HCC","Hepatitis B Virus Related Hepatocellular Carcinoma","Hepatocellular Carcinoma","2024-09-25",{"date":111,"type":112},"2024-09-27","ACTUAL",{"date":114,"type":112},"2022-10-25",{"date":116,"type":100},"2025-12-31",{"name":5,"class":6},7]